SCHEMBL6785189

SCHEMBL6785189

C/C(=C/C(=O)Nc1ccccc1C(=O)O)c1ccc(Cl)c(Br)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.67
TRPA1 O75762 3/20 0.47
TRPM8 Q7Z2W7 3/20 0.47
MEN1 O00255 4/20 0.46
ALDH1A1 P00352 4/20 0.46
KMT2A Q03164 4/20 0.46
RAB9A P51151 4/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.46
KCNH2 Q12809 1/20 0.46
HPGD P15428 3/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NFKB1 P19838 1/20 0.45
GFER P55789 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
DHODH Q02127 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025243 0.91 TERT (0.67) TERTTRPA1TRPM8MEN1ALDH1A1
SCHEMBL6785990 0.89 TERT (0.72) TERTTRPA1TRPM8MEN1ALDH1A1
SCHEMBL6523512 0.89 TERT (0.72) TERTTRPA1TRPM8MEN1ALDH1A1
SCHEMBL6785403 0.89 TERT (0.53) TERTMEN1ALDH1A1KMT2ARAB9A
SCHEMBL6785190 0.82 KDM4E (0.51) TERTMEN1ALDH1A1KMT2AHPGD
SCHEMBL6786210 0.81 TERT (0.61) TERTTRPA1TRPM8MEN1ALDH1A1
SCHEMBL30760782 0.81 TERT (1.00) TERTMEN1ALDH1A1KMT2ARAB9A
SCHEMBL16964998 0.81 TERT (1.00) TERTMEN1ALDH1A1KMT2ARAB9A
SCHEMBL4022937 0.81 TERT (1.00) TERTMEN1ALDH1A1KMT2ARAB9A
SCHEMBL111092 0.81 TERT (0.73) TERTTRPM8MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US claimed
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885TRPA1 4750/4885TRPM8 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.